Located near the town of Clayton, North Carolina, our facility manufactures insulin products for individuals with diabetes. The products manufactured at the Clayton plant are marketed in North America, Europe, New Zealand and Australia.
Located in Seattle, the research center builds upon Novo Nordisk's strong knowledge within the field of proteins, in order to further build the company's clinical pipeline of products for the treatment of chronic inflammatory diseases. The research activities in Seattle complement the biopharmaceutical research projects in Novo Nordisk's research sites in Måløv, Denmark and Beijing.
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)